Methods for treating cancer using TOR kinase inhibitor combination therapy

Patent metadata

Field	Value
Publication number	US-9782427-B2
Application number	US-201414254009-A
Country	US
Kind code	B2
Filing date	Apr 16, 2014
Priority date	Apr 17, 2013
Publication date	Oct 10, 2017
Grant date	Oct 10, 2017

Abstract

Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor having the following formula (I):

and an effective amount of a cytidine analog, such as 5-azacytidine, to a patient having a cancer.

First claim

What is claimed is:

1. A method for treating liver cancer or breast cancer, comprising administering an effective amount of a TOR kinase inhibitor in combination with an effective amount of 5 azacytidine to a patient having liver cancer or breast cancer, wherein the TOR kinase inhibitor is 1-ethyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or 7-(6-(2-hydroxypropan-2-yl)pyridin-3 -yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3 -b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

2. The method of claim 1 , wherein the cancer is a relapsed or refractory cancer.

3. The method of claim 1 , wherein the cancer is an advanced cancer.

4. The method of claim 1 , wherein the breast cancer is, hormone receptor positive, estrogen receptor positive (ER+, ER+/Her2 or ER+/Her2+), estrogen receptor negative (ER−/Her2+) or triple negative (TN).

5. The method of claim 1 , wherein the cancer is a cancer associated with the pathways involving mTOR, PI3K, or Akt kinases and mutants or isoforms thereof.

6. The method of claim 1 , wherein the cancer is liver cancer.

7. The method of claim 1 , wherein the cancer is breast cancer.

8. The method of claim 1 , wherein the TOR kinase inhibitor is 1-ethyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

9. The method of claim 1 , wherein the TOR kinase inhibitor is 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

Assignees

• Signal Pharm Llc

Inventors

• Raymon Heather

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P15/00

  Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title